Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 124, Issue 3, 2012, Pages 575-581

  Tian, Chunqiao ^a   Ambrosone, Christine B ^b   Darcy, Kathleen M ^a   Krivak, Thomas C ^c   Armstrong, Deborah K ^d   Bookman, Michael A ^e   Davis, Warren ^c   Zhao, Hua ^b   Moysich, Kirsten ^b   Gallion, Holly ^f   Deloia, Julie A ^g  

^a Buffalo Niagara Enterprise   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

^f Pikeville Medical Center   (United States)

^g GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

ABCB1; ABCC2; Advanced stage ovarian cancer; Common variants; GOG

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER C2; BREAST CANCER RESISTANCE PROTEIN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; GENOMIC DNA; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE; TOPOTECAN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM CANCER; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP-BINDING CASSETTE TRANSPORTERS; CARBOPLATIN; CISPLATIN; DEOXYCYTIDINE; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; POLYMORPHISM, GENETIC; TOPOTECAN; YOUNG ADULT;

EID: 84856746185     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.11.022     Document Type: Article

References (52)

1. S.A. Cannistra Cancer of the Ovary N Engl J Med 351 2005 2519 2529
2. W.P. McGuire Current status of taxane and platinum-based chemotherapy in ovarian cancer J Clin Oncol 21 10 Suppl. 2003 133s 135s
3. R.F. Ozols Systemic therapy for ovarian cancer: current status and new treatments Semin Oncol 33 2 Suppl. 6 2006 S3 S11
4. S. Modok, H.R. Mellor, and R. Callaghan Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer Curr Opin Pharmacol 6 2006 350 354
5. F.J. Sharom ABC multidrug transporters: structure, function and role in chemoresistance Pharmacogenomics 9 2008 105 127
6. L. Kelland The resurgence of platinum-based cancer chemotherapy Nat Rev Cancer 7 2007 573 584
7. M. Dean, A. Rzhetsky, and R. Allikmets The human ATP-binding cassette (ABC) transporter superfamily Genome Res 11 2007 1156 1166
8. V. Auner, J. Sehouli, G. Oskay-Oezcelik, R. Horvat, P. Speiser, and R. Zeillinger ABC transporter gene expression in benign and malignant ovarian tissue Gynecol Oncol 117 2010 198 201
9. R.Z. Yusuf, Z. Duan, D.E. Lamendola, R.T. Penson, and M.V. Seiden Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation Curr Cancer Drug Targets 3 2003 1 19
10. M.M. Baekelandt, R. Holm, J.M. Nesland, C.G. Tropé, and G.B. Kristensen P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer Anticancer Res 20 2000 1061 1067
11. A.D. Guminski, R.L. Balleine, Y.E. Chiew, L.R. Webster, M. Tapner, and G.C. Farrell MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma Gynecol Oncol 100 2006 239 246
12. P. Surowiak, V. Materna, I. Kaplenko, M. Spaczynski, B. Dolinska-Krajewska, and E. Gebarowska ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome Clin Cancer Res 12 2006 7149 7158
13. M.T. Huisman, A.A. Chhatter, O. van Tellingen, J.H. Beijnen, and A.H. Schinkel MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid Int J Cancer 116 2005 824 829
14. J.S. Lagas, M.L. Vlaming, O. van Tellingen, E. Wagenaar, R.S. Jansen, and H. Rosing Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics Clin Cancer Res 12 20 Pt 1 2006 6125 6132
15. R.W. Robey, O. Polgar, J. Deeken, K.W. To, and S.E. Bates ABCG2: Determining its relevance in clinical drug resistance Cancer Metastasis Rev 26 2007 39 57
16. K. Yoh, G. Ishii, T. Yokose, Y. Minegishi, K. Tsuta, and K. Goto Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer Clin Cancer Res 10 2004 1691 1697
17. R.W. Robey, K.K. To, O. Polgar, M. Dohse, P. Fetsch, and M. Dean ABCG2: a perspective Adv Drug Deliv Rev 61 2009 3 13
18. T. Litman, M. Brangi, E. Hudson, P. Fetsch, A. Abati, and D.D. Ross The multidrug-resistant phenotype associated with over expression of the new ABC half-transporter, MXR (ABCG2) J Cell Sci 113 Pt 11 2003 2011 2021
19. M. Wada Single nucleotide polymorphisms in ABCC2 and ABCB1 genes and their clinical impact in physiology and drug response Cancer Lett 234 2006 40 50
20. J. Cervenak, H. Andrikovics, C. Ozvegy-Laczka, A. Tordai, K. Német, and A. Váradi The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology Cancer Lett 234 2006 62 72
21. K. Yanase, S. Tsukahara, J. Mitsuhashi, and Y. Sugimoto Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development Cancer Lett 234 2006 73 80
22. K. Morisaki, R.W. Robey, C. Ozvegy-Laczka, Y. Honjo, O. Polgar, and K. Steadman Single nucleotide polymorphisms modify the transporter activity of ABCG2 Cancer Chemother Pharmacol 56 2005 161 172
23. T. Furukawa, K. Wakabayashi, A. Tamura, H. Nakagawa, Y. Morishima, and Y. Osawa Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations Pharm Res 26 2009 469 479
24. E.K. Pollex, G. Anger, J. Hutson, G. Koren, and M. Piquette-Miller Breast cancer resistance protein (BCRP)-mediated glyburide transport: effect of the C421A/Q141K BCRP single-nucleotide polymorphism Drug Metab Dispos 38 2010 740 744
25. D.K. Armstrong, B. Bundy, L. Wenzel, H.Q. Huang, R. Baergen, and S. Lele Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med 354 2006 34 43
26. M.A. Bookman, M.F. Brady, W.P. McGuire, P.G. Harper, D.S. Alberts, and M. Friedlander Evaluation of New Platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer InterGroup (GCIG) J Clin Oncol 27 2009 1419 1425
27. B.E. Baysal, J.A. DeLoia, J.E. Willett-Brozick, M.T. Goodman, M.F. Brady, and F. Modugno Analysis of CHEK2 gene for ovarian cancer susceptibility Gynecol Oncol 95 2004 62 69
28. J.R. Weiss, M.R. Baer, C.B. Ambrosone, J.G. Blanco, A. Hutson, and L.A. Ford Concordance of pharmacogenetic polymorphisms in tumor and germ line DNA in adult patients with acute myeloid leukemia Cancer Epidemiol Biomarkers Prev 16 2007 1038 1041
29. W.E. Winter III, G.L. Maxwell, C. Tian, J.W. Carlson, R.F. Ozols, and P.G. Rose Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 2007 3621 3627
30. L.A. Doyle, W. Yang, L.V. Abruzzo, T Krogmann, Y. Gao, and A.K. Rishi A multidrug resistance transporter from human MCF-7 breast cancer cells Proc Natl Acad Sci USA 95 1998 15665 15670
31. Q. Mao, and J.D. Unadkat Role of the breast cancer resistance protein (ABCG2) in drug transport AAPS J 7 2005 E118 E133
32. S. Ota, G. Ishii, K. Goto, K. Kubota, Y.H. Kim, and M. Kojika Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy Lung Cancer 64 2009 98 104
33. Y.H. Kim, G. Ishii, K. Goto, S. Ota, K. Kubota, and Y. Murata Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer Lung Cancer 65 2009 105 111
34. T.A. Brooks, H. Minderman, K.L. O'Loughlin, P. Pera, I. Ojima, and M.R. Baer Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein Mol Cancer Ther 2 2003 1195 1205
35. M. Maliepaard, M.A. van Gastelen, L.A. de Jong, D. Pluim, R.C. van Waardenburg, and M.C. Ruevekamp-Helmers Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line Cancer Res 59 1999 4559 4563
36. S. Mizuarai, N. Aozasa, and H. Kotani Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2 Int J Cancer 109 2004 238 246
37. Y. Imai, M. Nakane, K. Kage, S. Tsukahara, E. Ishikawa, and T. Tsuruo C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance Mol Cancer Ther 1 2002 611 616
38. E.E. Bram, I. Ifergan, M. Grimberg, K. Lemke, A. Skladanowski, and Y.G. Assaraf C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells Biochem Pharmacol 74 2007 41 53
39. A. Sparreboom, W.J. Loos, H. Burger, T.M. Sissung, J. Verweij, and W.D. Figg Effect of ABCG2 genotype on the oral bioavailability of topotecan Cancer Biol Ther 4 2005 650 658
40. S. Marsh, J. Paul, C.R. King, G. Gifford, H.L. McLeod, and R. Brown Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer J Clin Oncol 25 2007 4528 4535
41. S. Hille, D.T. Rein, M. Riffelmann, R. Neumann, J. Sartorius, and A. Pfützner Anticancer drugs induce MDR1 gene expression in recurrent ovarian cancer Anticancer Drugs 17 2006 1041 1044
42. Z. Duan, K.A. Brakora, and M.V. Seiden Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells Mol Cancer Ther 3 2004 833 838
43. R.T. Penson, E. Oliva, S.J. Skates, T. Glyptis, AF Fuller Jr., and A. Goodman Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples Gynecol Oncol 93 2004 98 106
44. M. Hitzl, S. Drescher, H. van der Kuip, E. Schäffeler, J. Fischer, and M. Schwab The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56 + natural killer cells Pharmacogenetics 11 2001 293 298
45. G.D. Leschziner, T. Andrew, M. Pirmohamed, and M.R. Johnson ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research Pharmacogenomics J 7 2007 154 179
46. M. Nakajima, Y. Fujiki, S. Kyo, T. Kanaya, M. Nakamura, and Y. Maida Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1 J Clin Pharmacol 45 2005 674 682
47. H. Gréen, P. Söderkvist, P. Rosenberg, G. Horvath, and C. Peterson mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy Clin Cancer Res 12 3 Pt 1 2006 854 859
48. S.E. Johnatty, J. Beesley, J. Paul, S. Fereday, A.B. Spurdle, and P.M. Webb ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy Clin Cancer Res 14 2008 5594 5601
49. V. Materna, B. Liedert, J. Thomale, and H. Lage Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells Int J Cancer 115 2005 393 402
50. S. Haenisch, K. May, D. Wegner, A. Caliebe, I. Cascorbi, and W. Siegmund Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol Pharmacogenet Genomics 18 2008 357 365
51. J.Y. Han, H.S. Lim, Y.K. Yoo, E.S. Shin, Y.H. Park, and S.Y. Lee Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan- pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer Cancer 110 2007 138 147
52. J.Y. Han, H.S. Lim, Y.K. Yoo, E.S. Shin, Y.H. Park, and S.Y. Lee Errata - Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan- pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer Cancer 116 15 2010 3749